Evidence map›Paper›PMID 42469912›Full record

ReviewOrphanet journal of rare diseases2026

French national diagnosis and care protocol (PNDS) for infantile idiopathic hypercalcemia (IIH).

Cyril Amouroux, Valérie Porquet-Bordes, Elodie Adler, Yoan Le Goff, Justine Bacchetta, Jean Philippe Bertocchio, Gilles Cambonie, Marie Courbebaisse, Odile Dicky, Thomas Edouard and 9 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Cyril AmourouxEndocrinology and Nephrology Unit, Multdisciplinary Paediatrics Department, Arnaud de Villeneuve Hospital, Montpellier, France.
Valérie Porquet-BordesEndocrine, Bone Diseases and Genetics Unit, Reference Centre for Rare Diseases of Calcium and Phosphate Metabolism, ERN BOND, OSCAR Network, Children's Hospital, Toulouse University Hospital, RESTORE, INSERM U1301, Toulouse, France.
Elodie AdlerAP-HP, Department of Pediatric Endocrinology, Hôpital Bicêtre Paris Saclay, Le Kremlin- Bicêtre, France.
Yoan Le GoffAP-HP, Department of Pediatric Endocrinology, Hôpital Bicêtre Paris Saclay, Le Kremlin- Bicêtre, France.
Justine BacchettaPathophysiology, Diagnosis and treatments of bone diseases, INSERM UMR1033, Lyon, France.
Jean Philippe BertocchioAP-HP, Pitié-Salpêtrière Hospital, Thyroid-Endocrine Tumors, Boulevard de l'hôpital, Paris, F-75013, France.
Gilles CambonieDepartment of Neonatal Medicine, Pediatric Intensive Care and Children's Acute Transport Service, Arnaud de Villeneuve Hospital, Montpellier University Hospital Centre, University of Montpellier, Montpellier, France.
Marie CourbebaisseGeorges Pompidou European Hospital, Physiology-Metabolic and Renal Functional Explorations Department, AP-HP, Paris Cité University, Reference Center for Rare Calcium and Phosphate Disorders (CaP) and Reference Center for Hereditary Kidney Diseases in Children and Adults (MARHEA), European Rare Kidney Disease Reference Network (ERKNet), Paris, France.
Odile DickyNeonatology and Neonatal Intensive Care Unit, Children's Hospital, Toulouse University Hospital CHU de Toulouse, Toulouse, France.
Thomas EdouardEndocrine, Bone Diseases and Genetics Unit, Reference Centre for Rare Diseases of Calcium and Phosphate Metabolism, ERN BOND, OSCAR Network, Children's Hospital, Toulouse University Hospital, RESTORE, INSERM U1301, Toulouse, France.
Barbara GirerdAP-HP, Department of Pediatric Endocrinology, Hôpital Bicêtre Paris Saclay, Le Kremlin- Bicêtre, France.
Vincent GuigonisDepartment of Pediatrics, Mother and Child Hospital, University Hospital of Limoges, Limoges, France.
Fairouz HalitimPrivate Pediatric Practice, 9 Rue Ernest Cresson, Paris, 75014, France.
Pascal HouillerGeorges Pompidou European Hospital, Physiology-Metabolic and Renal Functional Explorations Department, AP-HP, Paris Cité University, Reference Center for Rare Calcium and Phosphate Disorders (CaP) and Reference Center for Hereditary Kidney Diseases in Children and Adults (MARHEA), European Rare Kidney Disease Reference Network (ERKNet), Paris, France.
Agnès LinglartAP-HP, Department of Pediatric Endocrinology, Hôpital Bicêtre Paris Saclay, Le Kremlin- Bicêtre, France.
Emeline MarquantAP-HM, Multidisciplinary Pediatrics Department, La Timone Children's Hospital, 264 Rue Saint Pierre, Marseille, 13005, France.
Denis MorinCHU Montpellier, Pediatric Nephrology and Endocrinology Department, SORARE Reference Center (Rare Kidney Diseases), Montpellier, 34295, France.
Jean Pierre SallesEndocrine, Bone Diseases and Genetics Unit, Reference Centre for Rare Diseases of Calcium and Phosphate Metabolism, ERN BOND, OSCAR Network, Children's Hospital, Toulouse University Hospital, RESTORE, INSERM U1301, Toulouse, France.
Anya RothenbuhlerAP-HP, Department of Pediatric Endocrinology, Hôpital Bicêtre Paris Saclay, Le Kremlin- Bicêtre, France. anya.rothenbuhler@aphp.fr.ORCID http://orcid.org/0000-0001-9246-5160

Funding

Direction Générale de l'offre de Soins Direction Générale de l'offre de Soins
6 · The paper itself

Abstract

The objective of this study was to establish a French National Diagnosis and Care Protocol (PNDS: Protocole National de Diagnostic et de Soins), with the aim of providing health professionals with free, open access synthesis on optimal management and care of patients with Infantile Idiopathic Hypercalcemia (IIH) ( https://www.has-sante.fr/jcms/p_3522489/fr/hypercalcemie-infantile-idiopathique-hii ). The process involved a critical review of the literature and a multidisciplinary expert consensus. IIH is a rare genetic disorder, with a prevalence estimated at 1 in 33,000. Its clinical manifestations (such as urinary stones or nephrocalcinosis) can appear at different ages. The pathophysiology of IHH is characterized by excessive 1,25(OH)2 vitamin D mediated dietary digestive calcium absorption. The underlying mechanism varies depending on the pathogenic variant involved, which is located in one of two genes, CYP24A1 or SLC34A1. The natural history and pathophysiology of IHH remain poorly understood and are underreported in the literature. Management of the disease varies according to the presentation and severity of hypercalcemia. Non-specific management strategies encompass the cessation of calcium intake, the discontinuation of native vitamin D supplementation, hyperhydration, and the occasional utilization of bisphosphonates. The necessity for long-term treatment, which may encompass both non-specific measures and specific interventions, depends on the severity and the genetic variant identified. Long-term follow-up appears essential, although there is limited data available, particularly for detecting complications of the disease, with nephrocalcinosis being the primary one.

Indexed as

HypercalcemiaCalciumFranceHumansInfantInfant, Newborn, DiseasesMetabolism, Inborn ErrorsSodium-Phosphate Cotransporter Proteins, Type IIaVitamin DVitamin D3 24-HydroxylaseCalciumCYP24A1 protein, humanSLC34A1 protein, humanSodium-Phosphate Cotransporter Proteins, Type IIaVitamin DVitamin D3 24-HydroxylaseFollow-upHypercalcemiaInfantile idiopathic hypercalcemiaManagement

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.